No apparent effect of naproxen on CSF markers of innate immune activation

por Meyer, Pierre‐François, Labonté, Anne, Rosa‐Neto, Pedro, Poirier, Judes, Breitner, John C. S.
Publicado 2019

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis

por Meyer, Pierre-François, Savard, Melissa, Poirier, Judes, Labonté, Anne, Rosa-Neto, Pedro, Weitz, Tara M., Town, Terrence, Breitner, John
Publicado 2018

Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum

por Nilsson, Nathalie I. V., Picard, Cynthia, Labonté, Anne, Köbe, Theresa, Meyer, Pierre-François, Villeneuve, Sylvia, Auld, Daniel, Poirier, Judes
Publicado 2021

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

por Meyer, Pierre-François, Tremblay-Mercier, Jennifer, Leoutsakos, Jeannie, Madjar, Cécile, Lafaille-Maignan, Marie-Élyse, Savard, Melissa, Rosa-Neto, Pedro, Poirier, Judes, Etienne, Pierre, Breitner, John
Publicado 2019

Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in‐depth exploration of seven established risk factors

por Peters, Ruth, Breitner, John, James, Sarah, Jicha, Gregory A., Meyer, Pierre‐Francois, Richards, Marcus, Smith, A. David, Yassine, Hussein N., Abner, Erin, Hainsworth, Atticus H., Kehoe, Patrick G., Beckett, Nigel, Weber, Christopher, Anderson, Craig, Anstey, Kaarin J., Dodge, Hiroko H.
Publicado 2021